Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients

The primary objective was to describe the pattern of use of panitumumab (Vectibix) in combination with chemotherapy in patients with wild-type rat sarcoma viral oncogene homolog (RAS) metastatic colorectal cancer (mCRC): as first-line treatment in combination with FOLFOX or FOLFIRI or second-line treatment in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan).